Skip to main content
. 2022 Sep 7;157(11):991–999. doi: 10.1001/jamasurg.2022.3907

Figure 1. Consolidated Standards of Reporting Trials (CONSORT) Diagram and Flowchart.

Figure 1.

A, CONSORT diagram for the radioactive iodine seed placement in the axilla with sentinel lymph node biopsy (RISAS) procedure. B, Flowchart of patients who underwent sentinel lymph node biopsy (SLNB) and the marking of a pathologically confirmed positive axillary lymph node with radioactive iodine seed (MARI) procedure. In 3 of 9 patients with lymph node–negative (ypN0) status based on SLNB, residual disease was found in the MARI node. ALND indicates axillary lymph node dissection; cN+, clinically node positive; FN, false negative; NAC, neoadjuvant chemotherapy; TN, true negative; TP, true positive; ypN+, lymph node metastasis.

aAt the patients’ request, only the RISAS procedure without completion ALND was performed (this decision was always made before the surgical procedure took place).

bThese numbers represent all patients in whom SLNB was performed (ie, RISAS procedure in 227 patients and SLNB only [without MARI] in 1 patient for a total of 228 patients for SLNB) or in whom the MARI procedure was performed (ie, RISAS procedure in 227 patients and MARI only [without SLNB] in 11 patients for a total of 238 patients for MARI).